What is Adcentrx Therapeutics?
Founded in 2021, Adcentrx Therapeutics operates at the intersection of advanced molecular biology and therapeutic development. The company is primarily focused on the engineering of protein conjugates, a sophisticated class of drugs designed to deliver potent therapeutic payloads with high specificity to cancer cells. By leveraging a unique platform that optimizes the stability and efficacy of these conjugates, Adcentrx aims to overcome the limitations of traditional chemotherapy and existing targeted therapies. Headquartered in California, the firm has rapidly established itself as a key player in the biotech sector, attracting high-profile institutional backing to support its mission of transforming the standard of care for oncology patients.
How much funding has Adcentrx Therapeutics raised?
Adcentrx Therapeutics has raised a total of $101M across 2 funding rounds:
Other Financing Round
$50M
Series A
$51M
Other Financing Round (2021): $50M with participation from Zoo Capital and CBC Group
Series A (2023): $51M led by Eight Roads, Partners Investment, F-Prime Capital Partners, Quan Capital, and Delta Capital
Key Investors in Adcentrx Therapeutics
F-Prime Capital Partners
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies.
Quan Capital
Quan Capital is a healthcare-focused global venture capital firm that invests in startups within the healthcare, pharmaceutical, and biotech sectors to grow future industry leaders.
Delta Capital
Delta Capital focuses on early growth equity investment, utilizing a value-investment approach to institutionalize portfolio companies and realize operational improvements.
What's next for Adcentrx Therapeutics?
With the successful closure of its Series A financing, Adcentrx Therapeutics is poised to scale its operational capabilities and expand its clinical pipeline. The influx of capital will likely be directed toward accelerating the preclinical and clinical evaluation of its lead candidates, as well as enhancing its internal research infrastructure. As the company moves forward, the focus will remain on achieving critical regulatory milestones and establishing strategic partnerships that can facilitate the commercialization of its therapeutic assets. The firm's ability to attract top-tier investors suggests a long-term strategy centered on sustainable growth and the potential for significant breakthroughs in the treatment of complex, life-threatening conditions.
See full Adcentrx Therapeutics company page
